Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis
| العنوان: | Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis |
|---|---|
| المؤلفون: | Franz J. Legat, Robert R. Müllegger, Angelika Hofer, M. Schütz‐Bergmayr, R. Tatarski, Gudrun Ratzinger, Hannes Trattner, Constanze Jonak, Franz Trautinger, Clemens Painsi, K. Wippel‐Slupetzky, Wolfgang Weger, H. Skvara, Martin Inzinger, Thomas Graier, Bernhard Lange-Asschenfeldt, Christine Bangert, Alexandra Gruber-Wackernagel, A. Mlynek, Robert Strohal, N. Häring, Philipp Wolf, C. Kölli, Erich Schmiedberger, Igor Vujic, Sylvia Selhofer, Wolfgang Salmhofer, Adrian Tanew, C. Ellersdorfer, Franz Quehenberger, B. Gruber, K. Prillinger, L. Richter, Matthias Schmuth, W. Saxinger, R. Lichem, Wolfram Hoetzenecker, P.G. Sator |
| المصدر: | The British Journal of Dermatology |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | medicine.medical_specialty, Epidemiology, Dermatology, Etanercept, Cohort Studies, 030207 dermatology & venereal diseases, 03 medical and health sciences, Psoriatic arthritis, 0302 clinical medicine, Psoriasis Area and Severity Index, Internal medicine, Ustekinumab, medicine, Adalimumab, Humans, Psoriasis, Registries, Survival rate, Retrospective Studies, Biological Products, business.industry, Original Articles, medicine.disease, Survival Rate, Ixekizumab, Treatment Outcome, Austria, Secukinumab, Female, business, medicine.drug |
| الوصف: | Summary Background Drug survival rates reflect efficacy and safety and may be influenced by the availability of alternative treatment options. Little is known about time‐dependent drug survival in psoriasis and the effect of increasing numbers of biologic treatment options. Objectives To determine whether drug survival is influenced by the availability of treatment options and by factors such as gender, psoriatic arthritis or previous biologic treatment. Methods This observational, retrospective, multicentre cohort study analysed data from patients registered in the Austrian Psoriasis Registry (PsoRA) who were treated with biologics between 1 January 2015 and 30 November 2019. Results A total of 1572 patients who received 1848 treatment cycles were included in this analysis. The highest long‐term Psoriasis Area and Severity Index improvement was observed after treatment with ixekizumab, followed by ustekinumab and secukinumab, adalimumab and etanercept. Overall, ustekinumab surpassed all other biologics in drug survival up to 48 months. However, when adjusted for biologic naïvety, its superiority vanished and drug survival rates were similar for ixekizumab (91·6%), secukinumab (90·2%) and ustekinumab (92·8%), all of them superior to adalimumab (76·5%) and etanercept (71·9%) at 12 months and beyond. Besides biologic non‐naïvety (2·10, P What is already known about this topic? Female gender and previous biologic exposure have been discussed as predictors for decreased drug survival in patients with psoriasis, but it remains unknown whether a time‐dependent increased availability of treatment options alters biologic drug survival. What does this study add? The increased availability of alternative biologic treatments over time leads to an elevated risk for treatment discontinuation overall; therefore, drug survival analysis has to be time adjusted.Moreover, the study reveals that the impact of previous biologic treatment on drug survival is tremendous and confirms worse drug survival in female patients. Linked Comment: Gniadecki. Br J Dermatol 2021; 184:996–997. |
| تدمد: | 1365-2133 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7b61960883df8ceec3fcb2ab165f620 https://pubmed.ncbi.nlm.nih.gov/33822355 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....d7b61960883df8ceec3fcb2ab165f620 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13652133 |
|---|